An update on current pharmacotherapy options in atopic dermatitis

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 11, 2014, Pages 1517-1524

  Reitamo, Sakari ^a   Remitz, Anita ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Adherence; Atopic dermatitis; Corticosteroids; Long term treatment; Maintenance treatment; Pimecrolimus; T cell subsets; Tacrolimus

Indexed keywords

AZATHIOPRINE; BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; COLLAGEN; CORTICOSTEROID; CYCLOSPORIN A; FILAGGRIN; FLUTICASONE PROPIONATE; HYDROCORTISONE BUTYRATE; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 31; INTERLEUKIN 4; METHOTREXATE; METHYLPREDNISOLONE ACEPONATE; MOMETASONE FUROATE; MYCOPHENOLIC ACID; PIMECROLIMUS; TACROLIMUS; THYMIC STROMAL LYMPHOPOIETIN; TOLL LIKE RECEPTOR 2; UROCANIC ACID; IMMUNOSUPPRESSIVE AGENT;

ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; COLLAGEN SYNTHESIS; CYTOKINE RELEASE; DRUG EFFICACY; FOLLICULITIS; HERPES SIMPLEX; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; MAINTENANCE THERAPY; MEDICATION COMPLIANCE; REVIEW; RISK BENEFIT ANALYSIS; SKIN PRURITUS; SYSTEMIC THERAPY; TH2 CELL; TOPICAL TREATMENT; TREATMENT OUTCOME; DERMATITIS, ATOPIC; IMMUNOLOGY; MAINTENANCE CHEMOTHERAPY; METABOLISM; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; DERMATITIS, ATOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONG-TERM CARE; MAINTENANCE CHEMOTHERAPY; MEDICATION ADHERENCE; TACROLIMUS; TREATMENT OUTCOME;

EID: 84921630278     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.915941     Document Type: Review

References (68)

1. Mihm MC Jr, Soter NA, Dvorak HF, et al. The structure of normal skin and the morphology of atopic eczema. J Invest Dermatol 1976;67:305-12
2. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are major predisposing factors for atopic dermatitis. Nat Genet 2006;38:441-6
3. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol 2013;132:1132-8
4. Spergel JM. From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol 2010;105:99-106
5. Dharmage SC, Lowe AJ, Matheson MC, et al. Atopic dermatitis and the atopic march revisited. Allergy 2014;69:17-27.3
6. Silverberg JI, Simpson EL. Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization. Pediatr Allergy Immunol 2013;24:476-86
7. Weidinger S, O’Sullivan M, Illig T, et al. Filaggrin mutations, atopic eczema, hay fever, and asthma in children. J Allergy Clin Immunol 2008;121:203-9
8. Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 2009;124(3 Suppl 2):R7-R12
9. Kezic S, O’Regan GM, Yau N, et al. Levels of filaggrin degradation products are influenced by both filaggrin genotype and atopic dermatitis severity. Allergy 2011;66:934-40
10. Warner JA, McGirt LY, Beck LA. Biomarkers of Th2 polarity are predictive of staphylococcal colonization in subjects with atopic dermatitis. Br J Dermatol 2009;160:183-5
11. Kuo I-H, Yoshida T, De Benedetto A, et al. The cutaneous innate immune response in patients with atopic dermatitis. J Allergy Clin Immunol 2013;131:266-78
12. Neis MM, Peters B, Dreuw A, et al. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol 2006;118:930-7
13. Schäkel K, Döbel T, Bosselman I. Future treatment options for atopic dermatitis -- small molecules and beyond. J Dermatol Sci 2014;73:91-100
14. Lebwohl MG, Del Rosso JQ, Abramovits W, et al. Pathways to managing atopic dermatitis. Consensus from the experts. J Clin Aesthet Dermatol 2013;6(7 Suppl):S3-7
15. Birnie AJ, Bath-Hextall FJ, Ravenscroft JC, et al. Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Cochrane Database Stst Rev 2008;3:CD003871
16. Wilson SR, Thé L, Batia LM, et al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell 2013;155:285-95
17. Garcia Ponte L, Ebert U. Frontiers of rapid itch relief: a review of methylprednisolone aceponate. J Eur Acad Dematol Venereol 2012;26(Suppl 6):9-13
18. Kim DH, Lee HJ, Park CW, et al. The clinical efficacy of mometasone furoate in multi-lamellar emulsion for eczema: a double-blinded crossover study. Ann Dermatol 2013;25:17-22
19. Koivukangas V, Karvonen J, Risteli J, et al. Topical mometasone furoate and betametasone-17-valerate decrease collagen synthesis to a similar extent in human skin in vivo. Br J Dermatol 1995;132:66-8
20. Haapasaari KM, Risteli J, Karvonen J, et al. Effect of hydrocortisone, methylprednisolone aceponate and momethasone furoate on collagen synthesis in human skin in vivo. Skin Pharmacol 1997;10:261-4
21. Green C, Colquitt JL, Kirby J, et al. Clinical and cost-effectiveness of oncedaily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation. Health Technol Assess 2004;8:1-120
22. Williams HC. Established corticosteroid creams should be applied only once daily in patients with atopic eczema. BMJ 2007;334:1272
23. Luger TA, Lahfa M, Fölster-Holst R, et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat 2004;15:169-78
24. Reitamo S, Ortonne JP, Sand C, et al. A multicentre, randomized, double-blind study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2005;152:1282-9
25. Mandelin J, Remitz A, Virtanen H, et al. One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis. Acta Derm Venereol 2010;90:170-4
26. Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002;147:528-37
27. Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 2003;326:1367-72
28. Glazenburg EJ, Wolkerstorfer A, Gerretsen AL, et al. Efficacy and safety of fluticasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis: differences betweeen boys and girls? Pediatr Allergy Immunol 2009;20:59-66
29. Veien NK, Olholm Larsen P, Thestrup-Pedersen K, et al. Long-term, intermittent treatment of chronic hand eczema with momethasone furoate. Br J Dermatol 1999;140:882-6
30. Peserico A, Städtler G, Sebastian M, et al. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol 2008;158:801-7
31. Bochelen D, Rudin M, Sauter A. Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischaemia/reperfusion injury. J Pharmacol Exp Ther 1999;288:653-9
32. Paller AS, Lebwohl M, Fleischer AB Jr, et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol 2005;52:810-22
33. Fleischer AB Jr, Abramovits W, Breneman D, et al. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. J Dermatolog Treat 2007;18:151-7
34. Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002;109:547-55
35. Bieber T, Vick K, Fölster-Holst R, et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of atopic dermatitis. Allergy 2007;62:184-9
36. Doss N, Reitamo S, Dubertret L, et al. Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial. Br J Dermatol 2009;161:427-34
37. Doss N, Kamoun MR, Dubertret L, et al. Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment. Pediatr Allergy Immunol 2010;21:321-9
38. Luger T, Van Leent EJ, Graeber M, et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001;144:788-94
39. Luger T, De Raeve L, Gelmetti C, et al. Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis: from medical needs to a new treatment algoritm. Eur J Dermatol 2013;23:758-66
40. Sugiura H, Uehara M, Hoshino N, et al. Long-term efficacy of tacrolimus ointment for recalcitrant facial erythema resistant to topical corticosteroids in adult patients with atopic dermatitis. Arch Dermatol 2000;136:1062-3
41. Spergel JM, Boguniewicz M, Paller AS, et al. Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial. Br J Dermatol 2007;157:378-81
42. Reitamo S, Wollenberg A, Schöpf E, et al. Safety and efficacy of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol 2000;136:999-1006
43. Reitamo S, Rustin M, Harper J, et al. A 4-year follow-up of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. Br J Dermatol 2008;159:942-51
44. Wollenberg A, Reitamo S, Girolomoni G, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 2008;63:742-50
45. Thaçi D, Reitamo S, Gonzalez Ensenat EA, et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis. Br J Dermatol 2008;159:1348-56
46. Reitamo S, Allsopp R. Treatment with twice weekly tacrolimus ointment in patients with moderate to severe atopic dermatitis: results from two randomized, multicentre, comparative studies. J Dermatolog Treat 2010;21:34-44
47. Hix E, Gustafson CJ, O’Neill JL, et al. Adherence to a five day treatment course of topical fluocinonide 0.1% cream in atopic dermatitis. Dermatol Online J 2013;19:20029
48. Kojima R, Fujiwara T, Matsuda A, et al. Factors associated with steroid phobia in caregivers of children with atopic dermatitis. Pediatr Dermatol 2013;30:29-35
49. Shah A, Yenzer BA, Feldman SR. Timing of return office visit affects adherence to topical treatment in patients with atopic dermatitis: an analysis of 5 studies. Cutis 2013;91:105-7
50. Schmitt J, Schäkel K, F€olster-Holst R, et al. Prednisolone vs ciclosporin for severe adult eczema. An investigator initiated double-blind placebo-controlled multicenter trial. Br J Dermatol 2010;162:661-8
51. Roekevisch E, Spuls PI, Kuester D, et al. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol 2014;133(2):429-38
52. Simon D, Bieber T. Systemic therapy for atopic dermatitis. Allergy 2014;69(1):46-55
53. Silverberg JI. Atopic dermatitis: an evidence-based treatment update. Am J Clin Dermatol 2014. [Epub ahead of print]
54. Sowden JM, Berth-Jones J, et al. Double-blind, controlled, crossover study of ciclosporin in adults with severe refractory atopic dermatitis. Lancet 1991;338:137-40
55. Berth-Jones J, Takwale A, Tan E, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebocontrolled, crossover trial. Br J Dermatol 2002;147:324-30
56. Schram ME, Roekevisch E, Leeflang MM, et al. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol 2011;128:353-9
57. Haeck IM, Knol MJ, Ten Berge O, et al. Enteric-coated mycophenolate sodium versus ciclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol 2011;64:1074-84
58. Pacor ML, Di Lorenzo G, Martinelli N, et al. Comparing tacrolimus ointment and oral ciclosporine in adult patients affected by atopic dermatitis: a randomized study. Clin Exp Allergy 2004;34:639-45
59. Hijnen DJ, Knol E, Bruijnzeel-Koomen C, et al. Ciclosporin A treatment is associated with increased serum immunoglobulin E levels in a subgroup of atopic dermatitis patients. Dermatitis 2007;18:163-5
60. Mandelin JM, Rubins A, Remitz A, et al. Long-term efficacy and tolerability of tacrolimus 0.03% ointment in infants: a two-year open-label study. Int J Dermatol 2012;51:104-10
61. Remitz A, Virtanen HM, Reitamo S, et al. Tacrolimus ointment in atopic blepharo-conjunctivitis does not seem to elevate intraocular pressure. Acta Ophthalmol 2011;89(3):e295-6
62. Kiiski V, Remitz A, Reitamo S, et al. Long-term safety of topical pimecrolimus and topical tacrolimus in atopic blepharo-concuncitivitis. JAMA Dermatol 2014. [Epub ahead of print]
63. Remitz A, Kyllönen H, Granlund H, Reitamo S. Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol 2001;107:196-7
64. Mandelin JM, Remitz A, Virtanen HM, et al. A 10-year open follow-up of eczema and respiratory symptoms in patients with topical tacrolimus for the first 4 years. J Dermatolog Treat 2010;21:167-70
65. Kyllönen H, Remitz A, Mandelin JM, et al. Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br J Dermatol 2004;150:1174-81
66. Virtanen H, Remitz A, Malmberg P, et al. Topical tacrolimus in the treatment of atopic dermatitis -- does it benefit the airways? A 4-year open follow-up. J Allergy Clin Immunol 2007;120:1464-6
67. Tennis P, Gelfand JM, Rothman KJ, et al. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J Dermatol 2011;165:465-73
68. Siegfried EC, Jaworski JC, Hebert AA. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. Am J Clin Dermatol 2013;14:163-78